Next, we performed subgroup analysis investigating impact of antiplatelet therapy on high-risk patients as previously identified (JAK2 mutated, elevated WBC count, absence of splenomegaly) but antiplatelet drugs were not associated with a better TFS either except for PV patients with elevated WBC (p = 0.046) and absence of splenomegaly (p = 0.017) (Supplementary Table S3). This evidence concerns the gene JAK2 and acquired polycythemia vera.